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insufficient with monotherapy. We evaluated the cost and resource utilisation, in 
the UK health care system, of three treatment scenarios: tamsulosin (0.4mg) mon-
otherapy; tolterodine (modified release, 4mg) + tamsulosin given concomitantly; 
and fixed-dose combination (FDC) of solifenacin 6mg + oral controlled absorption 
system [OCAS™] formulation of tamsulosin (TOCAS, 0.4mg). Methods: A Markov 
model, with a monthly cycle length and 1-year time horizon, compared the cost of 
treating 1,000 men with LUTS/BPH who have moderate-to-severe storage symp-
toms and voiding symptoms. All patients were initially treated with tamsulosin 
monotherapy. Patients with inadequately controlled symptoms at week 12, based 
on Total Urgency and Frequency Score (TUFS, the daily sum of all recorded Patient 
Perception of Intensity of Urgency Scale [PPIUS] scores from micturition diaries), 
were considered for FDC solifenacin 6mg + TOCAS or tolterodine + tamsulosin. 
Patients adequately controlled at week 12 continued tamsulosin monotherapy. 
Thereafter, patients could discontinue therapy each month based on reported 
medication persistence data. Patients who discontinued treatment were eligible 
for surgery or other medical management. Results: Compared with tamsulosin 
monotherapy, total costs per patient, over a 1-year time horizon, were reduced by 
£133.75 for tolterodine + tamsulosin and reduced by £154.85 for FDC solifenacin 
6mg + TOCAS. ConClusions: Our findings suggest FDC solifenacin 6mg + TOCAS 
reduces annual health care costs compared with tamsulosin monotherapy and 
tolterodine + tamsulosin in patients with inadequately controlled storage symp-
toms. Lower total cost for FDC solifenacin 6mg + TOCAS and tolterodine + tamsu-
losin versus tamsulosin monotherapy was largely driven by improved symptom 
control. The relatively lower total cost for FDC solifenacin 6mg + TOCAS versus 
tolterodine + tamsulosin (£21 per patient/year) was principally due to improved 
persistence with FDC solifenacin 6mg + TOCAS.
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objeCtives: Combination therapy with an α -blocker and an antimuscarinic is 
recommended for men with moderate-to-severe LUTS/BPH if symptom relief is 
insufficient with monotherapy. We evaluated the cost-effectiveness of fixed-dose 
combination (FDC) solifenacin 6mg + oral controlled absorption system (OCAS™) 
formulation of tamsulosin (TOCAS, 0.4mg) versus tolterodine (modified release, 
4mg) + tamsulosin (0.4mg) given concomitantly, from the perspective of the UK 
NHS. Methods: A Markov model, with a time horizon of 1 year, was developed for 
men with LUTS/BPH who have moderate-to-severe storage symptoms (≥ 8 micturi-
tions/day and ≥ 2 urgency episodes/day [Patient Perception of Intensity of Urgency 
Scale, PPIUS, grade 3 or 4]) and voiding symptoms treated with FDC solifenacin 
6mg + TOCAS or tolterodine + tamsulosin. Treatment success was defined using 
the Total Urgency and Frequency Score (TUFS, the daily sum of all recorded PPIUS 
scores from micturition diaries). The phase 3 NEPTUNE study was used to estimate 
transition probabilities and utilities were derived from analysis of EQ-5D data. Other 
model input parameters included discontinuation rates, derived from a large UK 
database study (THIN). Univariate and probabilistic sensitivity analyses were per-
formed. Results: FDC solifenacin 6mg + TOCAS was associated with lower total 
annual costs (£520 vs £583) and increased quality adjusted life years (QALYs, 0.840 
vs. 0.838), and was therefore dominant compared with tolterodine + tamsulosin. 
Time horizon, discontinuation/withdrawal rates, drug cost and utility values were 
the main drivers of cost-effectiveness. The probability that FDC solifenacin 6mg + 
TOCAS is cost-effective was 100% versus tolterodine + tamsulosin, at a willingness 
to pay threshold of £20,000/QALY gained. ConClusions: FDC solifenacin 6mg + 
TOCAS is dominant compared with tolterodine + tamsulosin for the treatment of 
men with LUTS/BPH who have moderate-to-severe storage symptoms and voiding 
symptoms. To our knowledge, this is the first cost-effectiveness analysis of a FDC 
in this patient population.
PUK22
EConomiC EffECts of trEAtmEnt of ChroniC KidnEy disEAsE With loW-
ProtEin diEt
Mennini F.S.1, Russo S.1, Marcellusi A.1, Quintaliani G.2, Fouque D.3
1University of Rome “Tor Vergata”, Rome, Italy, 2Silvestrini Hospital, Perugia, Italy., Perugia, 
Italy, 3Centre Hospitalier Lyon Sud, Center for European Nutrition and Safety, Université de Lyon, 
France, Lyon, France
objeCtives: The most recent literature has shown extensively that a low protein 
diet in patients with Chronic Kidney Disease (CKD), delays the natural progres-
sion of the end stage renal disease (ESRD) and the necessary treatment of chronic 
dialysis. The aim of this study is to estimate the cost-effectiveness of a low protein 
diet compared with no dietary treatment in patients with CKD stage 4 and 5 after 
2, 3, 5 and 10 years. Methods: It was developed a Markov model to estimate 
costs and QALYs associated with low protein diet versus no treatment for patients 
with CKD stage 4-5. The transition probability was estimated on data from seven 
studies which determined the efficacy of low protein diets in delaying the need 
to start maintenance dialysis. Utilities and cost were estimated from literature 
review and projected for the lifespan considered in the model. The annual cost 
of dialysis per patient was approximately € 34,072. The costs of a low-protein diet 
was € 1,440 per patient per year in the Lazio Region (conservative assumptions). 
Probabilistic and Deterministic sensitivity analysis were performed. Results: The 
model estimate that low-protein diet should be more effective. Dietary treatment 
improve 0.09 QALYs after two years, 0.16 after three years, 0.36 after five years and 
up to 0.93 incremental QALYs after the first 10 years. After two years the model 
estimate incremental cost in favour of dietary treatment of € 1,325, € 3,023, € 6,906 
and € 13,829 for 2, 3, 5 and 10 years of follow-up respectively. ConClusions: The 
results of these simulations indicate that the treatment of CKD patients with a 
objeCtives: To analyze the cost of hemodialysis (HD) and peritoneal dialysis (PD) 
in different regions of Russia. Methods: Open source information search. Direct 
cost analysis. Results: During the information search current tariffs have been 
found for 25 regions for HD and for 11 regions for PD. Tariff per one HD procedure 
has ranged from $ 96 for the republic Chuvashia to $ 319 for the the Khanty-Mansi 
Autonomous Area, i.e. annual cost of the HD per patient amounted to $ 14976 
and $ 49764, respectively. The cost of a single procedure HD in Moscow was $ 162, 
which corresponds to an annual expenditure of approximately $ 25272 per patient. 
 The average cost of the procedure HD in the Russia amounted to about $ 150 
and the annual cost of HD for one patient - $ 23400. The cost of one exchange 
PD ranged from $ 15 in the Nizhny Novgorod region to $ 84 in the Khanty-Mansi 
Autonomous Area. Thus, the annual costs on the PD upon 4 exchanges per day for 
per patient in these regions were $ 21900 and $ 122640, respectively. The cost of 
one PD exchange in Moscow was $ 26, which corresponds to an annual expendi-
ture of approximately $ 37960 per patient. The average cost of one exchange PD 
in Russia amounted to $ 22, and the average annual cost per patient - $ 32120 
(accepted exchange rate was 1 $ = 33,35 RUB). ConClusions: Thus, during the 
cost analysis it has been revealed that the cost of dialysis among the subjects of 
Russia differs in more than 3 times, despite the fact that the same set of medical 
services is provided in each region.
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objeCtives: To understand the trends in rate and cost of hospitalizations due 
to Chronic Kidney Disease (CKD) in the U.S. Methods: We analyzed the last five 
years of hospitalizations with ICD-9 diagnosis codes of CKD and End Stage Renal 
Disease (ESRD). The annual number of hospitalizations for specific diagnosis was 
obtained from AHRQ’s National In-patient Sample (NIS) databases of 2005-2009. 
Data was also analyzed for length of stay (LOS), charges and cost of hospitaliza-
tion. Results: During the last five years the number of hospitalizations with 
diagnosis of CKD and ESRD has increased 4.1 and 4.6 fold, respectively. In 2009, 
an estimated 1,634,422 and 931,641 hospitalizations were with diagnosis of CKD 
and ESRD respectively. The mean LOS for patients with CKD increased from 4.9 to 
5.5 days between2005-2009. The mean LOS for patients with ESRD has remained 
steady at ~6 days between 2005-2009. The cost of hospitalization with diagnosis 
of CKD has increased 31% between 2005-2009. The cost of hospitalization with 
diagnosis of ESRD has increased 21% between 2005-2009. In 2009, the mean cost of 
hospitalization for patients with CKD and ESRD was $11,209 and $21,358, respec-
tively. ConClusions: Hospitalizations due to CKD and ESRD have significantly 
increased during the last five years. There is a need for prevention, treatment, and 
disease management programs to lower the medical and socioeconomic burden 
of this disease.
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objeCtives: Although delayed graft function (DGF) on kidney transplantation 
outcomes have been associated with worse allograft and patient survival, the cost 
impact has not been recently explored using a large retrospective database and 
assessed after transplantation hospitalization. Our objective was to determine the 
financial impact of delayed graft function (DGF) in primary kidney transplant recipi-
ents of deceased (DD) and living donor (LD) recipients in the early post-operative 
and long-term follow-up periods. Methods: A retrospective analysis of USRDS 
and Medicare claims from 2004-2009. Subjects excluded were multiple transplants, 
donor < 5 yo, and transplantation payments < $15,000. DGF was defined at requiring 
dialysis within the first week post-transplantation. Total direct medical costs were 
assessed for 1, 3, 6, 12, 24, and 36-month time intervals post-transplant. Uni-variate 
analyses of covariates were assessed for association with log-transformed charges. 
Significant variables (p< 0.05) were included in multivariate regression. Base charge 
was calculated using an mean of standard demographic and outcome characteris-
tics. Results: After application of exclusion criteria and data validation, 22,616 DD 
and 7,373 LD recipients were evaluated. In multivariate analysis, DGF was an inde-
pendent predictor of charges at 1, 3, 6, and 12 months of $3,920 (p< 0.0001), $1,962 
(p< 0.0001), $839 (p= 0.006) and $1,026 (p= 0.019), respectively in DD. In LD, DGF was 
an independent predictor of charges at 1, 3, and 6 months of $145 (p= 0.012), $4,558 
(p< 0.0001), and $3,629 (p= 0.001), respectively. ConClusions: DGF is a significant 
independent predictor of greater health resource utilization in renal transplanta-
tion that impacts costs beyond the transplant hospitalization. This impact extends 
longer in DD compared to LD. This information should be considered in addition to 
clinical outcomes expected based on the individual transplant candidate to deter-
mine likelihood of successful patient and allograft outcomes.
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objeCtives: Combination therapy with an α -blocker and an antimuscarinic is 
recommended for men with moderate-to-severe LUTS/BPH if symptom relief is 
